the mda sent out the following update this morning july , legislation ensuring access to clinical trials for people with neuromuscular diseases passes u s senate on july , , the u s senate passed the ensuring access to clinical trials act s , which removes barriers for those with neuromuscular and other rare diseases to participate in clinical trials the bipartisan legislation makes permanent the improving access to clinical trials act of iact that is scheduled to expire in october the bill stipulates that up to , of compensation will not be counted as income toward patients' eligibility for supplemental security income ssi or medicaid by making the iact permanent , those with muscular dystrophy , amyotrophic lateral sclerosis als , spinal muscular atrophy sma and other neuromuscular and rare diseases will be able to continue to participate in clinical trials without the risk of losing vital benefits mda is proud to partner with the cystic fibrosis foundation , the national organization for rare disorders , and more than seventy other groups who together represent millions of individuals in support of the ensuring access to clinical trials act of eact s h r an identical bill is currently pending in the u s house of representatives h r please click the button below to receive advocacy alerts and updates about this and other important policy initiatives it is good to hear that more than organizations have come together to support the passage of this act additional information and details about the act can be found at congress gov